EyePoint Pharmaceuticals, Inc. — Director's Dealing 2025

Jun 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2025-06-23

Reporting Person: Duker Jay S. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-23	Common Stock	J	56665.00	$8.21	Disposed	986.00	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	99165.00	Indirect

Footnotes

F1: The shares were sold by the reporting person to the Duker Family 2024 Irrevocable Trust, or the Family Trust, in exchange for a promissory note in the principal amount of $465,219.65, representing the fair market value as determined by utilizing the average of the high and low per share trading price on the date of the sale. The shares held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.